PixarBio’s NeuroRelease™ A Revolutionary Non Addictive Pain Treatment Draws Pain Industry Star Sales Executive David Kaplan as Global VP of Sales & Marketing

CAMBRIDGE, Mass.--()--PixarBio Corporation inventors of NeuroRelease, a 14 day non-addictive post-surgical pain treatment with expected FDA approval in 2018, announced today the appointment of David Kaplan as Vice President of Global Sales and Marketing.

David joins PixarBio from Pacira Pharmaceuticals where he was Vice President of Sales, responsible for US sales and for leading the successful relaunch of post-op pain drug Exparel.

David will report to Frank Reynolds, the company’s founder and Chief Executive Officer. David is another important piece to the company’s growing leadership infrastructure, and in maintaining momentum toward commercialization of NeuroRelease™, PixarBio’s Morphine Strength Non-Addictive Pain Treatment™ with expected FDA approvals in 2018.

David brings over twenty-five years of hands-on commercial industry experience, including thirteen years of executive sales leadership to PixarBio Corporation. His unique combination of big pharma, and start-up pharmaceutical company experience combined with his leadership style, and ability to create and sustain positive economically vibrant cultures is a perfect fit for PixarBio at this time. He was at Pacira Pharmaceuticals for the past three years, most recently as their Vice President of Sales where he was responsible for all North American Sales for the launch of Exparel.

David will develop and execute PixarBio Corporation’s global sales strategy for all pre-commercial and commercial initiatives around their lead development product NeuroRelease™. David will also be responsible for the global sales strategy for all PixarBio Corporation product launches, and accountable for all facets of product roll-out and launch, sales forecasts, sales budgets, and maximizing cross-functional teams.

David is a proven leader with a commitment to overachieving, resulting in an outstanding track record of product launches and company sales. He brings excellent business acumen to the hospital c-suite and his efforts in redesigning Pacira’s sales organization resulted in 40% of additional sales growth of Exparel, the only FDA approved post-op pain treatment. He is recognized as a true people leader. David lives in New Jersey with his wife and he will work out of the PixarBio-New York Office.

“David a perfect fit for our innovation engine. Our powerful R&D portfolio is drawing industry leaders like David to take PixarBio from product launch through to market saturation. True industry stars require innovative cultures to achieve the impossible dreams that we lay out for our teams every day. Success has 1,000 fathers and failure none, but we all know what David Kaplan delivered to the Post-Op Pain Industry. We will continue to out-invent our competition in the non-addictive pain space and provide David with all the pain product he can sell from 2018 through 2034," said PixarBio CEO Frank Reynolds.

About PixarBio Corporation
Cofounded by Frank M. Reynolds, MIT’s Dr. Robert S. Langer, Katrin Holzhaus, and Dr. Jason Criscione, PixarBio researches and develops targeted delivery systems for drugs, cells, or biologics to treat pain, epilepsy, Parkinson’s disease, and spinal cord injury. For more information visit www.pixarbio.com.

Contacts

PixarBio Corporation

Glenn Reiser

617-803-8838

Vice President, External Affairs

investorrelations@pixarbio.com

Recent Stories

RSS feed for PixarBio Corporation